col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Future Medicine: Immunotherapy
  original article Date Title Authors   All Authors
1 [GO] 2021―Jun―11 Appropriate use of antimicrobial therapy for COVID-19 co-infection Chih-Cheng Lai, Wen-Liang Yu
2 [GO] 2021―Apr―28 Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) Marcelo Maia Pinheiro, Andrea Fabbri, Marco Infante
3 [GO] 2021―Feb―09 Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma Shaukat Ali, Syed M Uddin, Ayesha Ali, Fatima Anjum, Rashid Ali, Elisha Shalim, et al. (+7)
4 [GO] 2021―Jan―05 An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases Lázaro Manuel Filgueira, Julio Betancourt Cervantes, Orlando Adolfo Lovelle, Carlos Herrera, Carlos Figueredo, Jorge Alain Caballero, et al. (+11)
5 [GO] 2020―Dec―14 Immunity to glycan α-Gal and possibilities for the control of COVID-19 José de la Fuente, Christian Gortázar, Alejandro Cabezas-Cruz
6 [GO] 2020―Sep―22 COVID-19 and the newly rediscovered multidisciplinarity Melissa Bersanelli
7 [GO] 2020―Sep―16 Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy Melissa Bersanelli, Teresa Zielli, Fabiana Perrone, Chiara Casartelli, Fabiana Pratticò, Elena Rapacchi, et al. (+9)
8 [GO] 2020―Sep―09 COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy Cesar Martins da Costa, Zenaide Silva de Souza, Alessandra Corte Real Salgues, Guilherme Harada, Pedro Paulo Marino Rodrigues Ayres, Daniela Bulhões Vieira Nunes, et al. (+2)
9 [GO] 2020―Sep―09 Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins José María Díez, Carolina Romero, Júlia Vergara-Alert, Melissa Belló-Perez, Jordi Rodon, José Manuel Honrubia, et al. (+4)
10 [GO] 2020―Jul―17 Obesity, COVID-19 and immunotherapy: the complex relationship! Carmine Finelli
11 [GO] 2020―Jul―15 Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients Juan David Cala-García, Juan David Sierra-Bretón, Jorge Eduardo Cavelier-Baiz, Álvaro A Faccini-Martínez, Carlos Eduardo Pérez-Díaz
12 [GO] 2020―Jul―09 How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology Ting Yi Jessica Chang, Janet E Pope
13 [GO] 2020―Jun―29 Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19 Lidia Gatto, Enrico Franceschi, Vincenzo Di Nunno, Alba Ariela Brandes
14 [GO] 2020―Jun―17 Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019 Megan Melody, Jared Nelson, Jacquelyn Hastings, Joshua Propst, Michael Smerina, Julio Mendez, Pramod Guru
15 [GO] 2020―Jun―03 Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors Patrizia Vici, Laura Pizzuti, Eriseld Krasniqi, Andrea Botticelli, Gennaro Ciliberto, Maddalena Barba
16 [GO] 2020―May―13 Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens José-María Díez, Carolina Romero, Rodrigo Gajardo
17 [GO] 2020―Apr―30 COVID-19: the use of immunotherapy in metastatic lung cancer Alexander P Davis, Michael Boyer, Jenny H Lee, Steven C Kao
18 [GO] 2020―Apr―15 Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Joseph Kattan, Clarisse Kattan, Tarek Assi
19 [GO] 2020―Mar―26 Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors Melissa Bersanelli


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.016 sec